ArticleAntimicrobial agents and chemotherapy2025
β-Lactamase diversity in
Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- In vitro activity of aztreonam-avibactam against carbapenem-resistant Pseudomonas aeruginosa from Southern Brazil.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Mechanisms involved in cefiderocol resistance in FrenchAntimicrobial agents and chemotherapy · 2026Article
- Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Emergence of KPC-producingAntimicrobial agents and chemotherapy · 2026Article
- Multimodal computational discovery of MvfR inhibitors targeting quorum sensing in multi-drug-resistant Pseudomonas aeruginosa.Scientific reports · 2026Article
- Identification of a novel gene inAntimicrobial agents and chemotherapy · 2026Article
- A Survey of the Microbiome, Culturome and ARG Profile of a Cohort of Chronic Diabetic Foot Lesions.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Article
- Genomic and clinical characteristics ofMicrobiology spectrum · 2026Article
- Integrated Phenotypic, Proteomic (MALDI-TOF MS), and Genomic (WGS) Investigation of a Prolonged Hospital Outbreak ofAntibiotics (Basel, Switzerland) · 2026Article
- Genomic Insights into Carbapenem-ResistantJournal of clinical medicine · 2026Article
- Database resources of the National Center for Biotechnology Information in 2026.Nucleic acids research · 2026Article
- Genetic Analysis of Virulence and β-Lactamase Determinants Related to β-Lactamase Inhibitors inAntibiotics (Basel, Switzerland) · 2025Article
- Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility inAntimicrobial agents and chemotherapy · 2025Article
- Antimicrobial Resistance Profiles ofPolish journal of microbiology · 2025Article
- Companion Animals as Reservoirs of Multidrug Resistance-A Rare Case of an XDR, NDM-1-ProducingVeterinary sciences · 2025Article
- Resistance to oxyimino-cephalosporins conferred by an alternative mechanism of hydrolysis by themBio · 2025Article
- Antibiotic Resistance and Virulence Determinants ofMicroorganisms · 2025Article
- Proteomic landscape of imipenem resistance inFrontiers in cellular and infection microbiology · 2025Article
- The Role ofInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.